Risk-Adjusting Mortality in the Nationwide Veterans Affairs Healthcare System

Hallie C Prescott, MD, MSc1,2, Rajendra P Kadel, Ph.D.4, Julie R Eyman, BA4, Ron Freyberg, MS4, Matthew Quarrick, MS4, David Brewer, BS4, and Rachael Hasselbeck, MSN, MBA, RN3

1VA Center for Clinical Management Research, Ann Arbor, MI, USA; 2University of Michigan, Department of Medicine, Ann Arbor, MI, USA; 3VA Inpatient Evaluation Center, Department of Veterans Affairs, Veterans Health Administration, 810 Vermont Ave. NW Room 668, Washington, DC, USA; 4VA Center for Strategic Analytics and Reporting, Department of Veterans Affairs, Veterans Health Administration, 810 Vermont Ave. NW Room 668, Washington, DC, USA.

BACKGROUND: The US Veterans Affairs (VA) healthcare system began reporting risk-adjusted mortality for intensive care (ICU) admissions in 2005. However, while the VA’s mortality model has been updated and adapted for risk-adjustment of all inpatient hospitalizations, recent model performance has not been published. We sought to assess the current performance of VA’s 4 standardized mortality models: acute care 30-day mortality (acute care SMR-30); ICU 30-day mortality (ICU SMR-30); acute care in-hospital mortality (acute care SMR); and ICU in-hospital mortality (ICU SMR).

METHODS: Retrospective cohort study with split derivation and validation samples. Standardized mortality models were fit using derivation data, with coefficients applied to the validation sample. Nationwide VA hospitalizations that met model inclusion criteria during fiscal years 2017–2018 (derivation) and 2019 (validation) were included. Model performance was evaluated using c-statistics to assess discrimination and comparison of observed versus predicted deaths to assess calibration.

RESULTS: Among 1,143,351 hospitalizations eligible for the acute care SMR-30 during 2017–2019, in-hospital mortality was 1.8%, and 30-day mortality was 4.3%. C-statistics for the SMR models in validation data were 0.870 (acute care SMR-30); 0.864 (ICU SMR-30); 0.914 (acute care SMR); and 0.887 (ICU SMR). There were 16,036 deaths (4.29% mortality) in the SMR-30 validation cohort versus 17,458 predicted deaths (4.67%), reflecting 0.38% over-prediction. Across deciles of predicted risk, the absolute difference in observed versus predicted percent mortality was a mean of 0.38%, with a maximum error of 1.81% seen in the highest-risk decile.

CONCLUSIONS AND RELEVANCE: The VA’s SMR models, which incorporate patient physiology on presentation, are highly predictive and demonstrate good calibration both overall and across risk deciles. The current SMR models perform similarly to the initial ICU SMR model, indicating appropriate adaption and recalibration.

KEY WORDS: hospital mortality; risk adjustment; logistic models.
Mortality models in operational use, we focused on the acute care 30-day mortality model because it is the most comprehensive (includes both ward and ICU patients, and captures both in-hospital and post-discharge mortality) and therefore the most important mortality model for overall performance assessment.

METHODS

Setting
The VA healthcare system is an integrated healthcare delivery system that provides comprehensive healthcare to Veterans. The VA was among the first healthcare delivery systems to have a universal electronic health record, and to measure and report risk-adjusted mortality.1

Mortality Models
As part of routine performance assessment, the VA measures and reports four standardized mortality ratios (SMRs) for each VA hospital on a quarterly basis: (1) acute care 30-day mortality (acute care SMR-30); (2) ICU 30-day mortality (ICU SMR-30); (3) acute care in-hospital mortality (acute care SMR); and (4) ICU in-hospital mortality (ICU SMR). The mortality models are each developed on a rolling 2-year look-back of VA hospitalizations, then applied to the current fiscal year. The inclusion criteria, definitions, and key differences of each SMR model are presented in Appendix 1 and Supplemental Table 1. A summary of key changes to the models since their last description is presented in Supplemental Table 2.

For the acute care models, predicted mortality is estimated using a logistic regression model that includes the following predictors: age, admitting diagnosis category, major surgical procedure category, 29 comorbid conditions, physiologic variables (PaO2, PaCO2, and pH) as well as hospital length of stay prior to ICU admission. For the ICU models, we also assessed model performance by level of intensive care, as defined by availability of subspecialty services.16 Finally, for the acute care SMR-30 model, we evaluated c-statistics in a series of nested models to understand the incremental impact of administrative and clinical data on model discrimination.

Data management and analysis were completed in SAS Enterprise Guide 8.3 (SAS Institute Inc., Cary, NC). Figures were produced in R. This study was approved by the Ann Arbor VA Institutional Review Board with a waiver of informed consent.

RESULTS

Cohort Characteristics
Among 1,996,645 inpatient stays during fiscal years 2017–2019, there were 1,143,351 acute care hospitalizations meeting criteria for the Acute Care SMR-30. Of 1,996,645...
inpatient stays, 673,813 (33.7%) were excluded due to a non-acute care treating specialty (e.g., nursing, psychiatry, and rehabilitation care), 114,068 (5.7%) because they occurred within 30 days of a prior hospitalization, 1,280 because they involved specialized treatments (organ transplantation of left ventricular assist device) (0.1%), 415 patients who died within 4 h of arrival (0.02%), and 20,011 with hospice care during the calendar day of admission or the preceding year (1.0%). Study flow diagrams showing the application of model exclusions for each SMR model are presented in Supplemental Tables 3 and 4, while Supplemental Table 5 shows the number of unique patients in the acute care and ICU SMR 30 models.

Acute care SMR-30 cohort characteristics and outcomes are presented in Table 1. Hospitalizations in the SMR-30 model were median age 68 years (IQR 61–74), 94.4% male, and 70.8% White, with a median of 3 comorbid conditions (IQR 2–5). The majority of hospitalizations were admitted via the emergency department or directly, while 15.1% were admitted from the operating room, 2.4% were transferred in from another hospital, and 1.9% were admitted from nursing facilities. The most common admission diagnosis categories were musculoskeletal injuries (7.5%), congestive heart failure (5.7%), non-sepsis/non-pneumonia infections (5.6%), neurological diseases (5.2%), and sepsis (4.5%). In-hospital mortality was 1.8%, and 30-day mortality was 4.3%. Patient characteristics were similar between the derivation (FY 2017–2018) and validation (FY 2019) cohorts. For the acute care SMR-30 validation cohort, predicted risk of 30-day mortality was median 1.6% (IQR 0.6%, 4.4%), mean 4.7% (Fig. 1).

### Table 1 Patients and Hospitalization Characteristics for Derivation, Validation, and Full Cohort for the Acute Care SMR-30 Model

|                             | Total cohort FY 2017–2019 | Derivation cohort FY 2017–2018 | Validation cohort FY 2019 |
|-----------------------------|----------------------------|--------------------------------|---------------------------|
| Hospitalizations, N         | 1,143,351                  | 769,924                        | 373,727                   |
| Unique patients, N          | 702,866                    | 512,868                        | 198,998                   |
| Male, % of hospitalizations | 94.4%                      | 94.5%                          | 94.2%                     |
| Self-reported race, % of hospitalizations |                      |                                |                           |
| White                       | 70.8%                      | 71.1%                          | 70.1%                     |
| Black or African American   | 21.5%                      | 21.3%                          | 22.1%                     |
| Other, unknown, or not reported | 7.7%                      | 7.6%                           | 7.8%                      |
| Age, median (IQR)           | 68 (61,74)                 | 68 (61,74)                     | 68 (61,75)                |
| Number of comorbid conditions, median (IQR) | 3 (2.5)                    | 2 (2.4)                        | 3 (2.5)                   |
| Select comorbid conditions, % of hospitalizations |                      |                                |                           |
| Congestive heart failure    | 12.7%                      | 12.2%                          | 13.7%                     |
| Chronic pulmonary disease   | 23.9%                      | 23.6%                          | 24.7%                     |
| Liver disease               | 7.7%                       | 7.6%                           | 8.0%                      |
| Metastatic cancer           | 2.4%                       | 2.4%                           | 2.6%                      |
| Immunosuppressed status (indicator in SMR models) | 22.5%                      | 22.2%                          | 23.1%                     |
| Admission Source            |                            |                                |                           |
| Other hospital (VA or non-VA)| 2.4%                       | 2.3%                           | 2.5%                      |
| Nursing home (VA or non-VA) | 1.9%                       | 1.8%                           | 2.0%                      |
| Operating Room             | 15.1%                      | 15.3%                          | 14.7%                     |
| Other (Emergency Department, Direct Admission) | 80.6%                      | 80.6%                          | 80.8%                     |
| Admitting diagnosis category*, % of hospitalizations |                      |                                |                           |
| Musculoskeletal (besides hip fracture) | 7.5%                       | 7.5%                           | 7.5%                      |
| Congestive heart failure    | 5.7%                       | 5.7%                           | 5.9%                      |
| Infections (besides sepsis or pneumonia) | 5.6%                       | 5.7%                           | 5.3%                      |
| Neurologic diseases         | 5.2%                       | 5.2%                           | 5.1%                      |
| Sepsis                      | 4.5%                       | 4.2%                           | 5.1%                      |
| Substance-related disorders | 4.3%                       | 4.2%                           | 4.4%                      |
| Chronic obstructive pulmonary disease | 4.0%                       | 4.1%                           | 3.9%                      |
| Cardiac dysrhythmias        | 3.7%                       | 3.6%                           | 3.7%                      |
| Other gastrointestinal disease | 3.7%                       | 3.8%                           | 3.7%                      |
| Complications of surgical/medical care | 3.5%                       | 3.5%                           | 3.6%                      |
| All other diagnosis categories | 52.3%                      | 52.5%                          | 51.8%                     |
| DRG grouping, % of hospitalizations |                      |                                |                           |
| Medical                     | 77.4%                      | 76.8%                          | 78.5%                     |
| Surgical                    | 21.6%                      | 21.7%                          | 21.3%                     |
| Major surgical procedure within 24 h, % | 15.5%                      | 15.7%                          | 15.1%                     |
| Length of hospitalization in days, median (IQR) | 2 (1.4)                    | 3 (1.4)                        | 2 (1.4)                   |
| ICU admission, % of hospitalizations |                      |                                |                           |
| Directly admitted directly to ICU | 14.4%                      | 14.4%                          | 14.2%                     |
| Ever admitted to ICU        | 18.0%                      | 18.1%                          | 17.8%                     |
| Mortality, % of hospitalizations |                      |                                |                           |
| In-hospital                 | 1.8%                       | 1.7%                           | 1.8%                      |
| 30-day                      | 4.3%                       | 4.3%                           | 4.3%                      |

*Hospitalizations were each assigned to one of 51 mutually exclusive diagnosis categories based on their admitting diagnosis. These diagnosis categories each include one or more clinical classification software (CCS) diagnosis categories. The consolidation of CCS categories into admission diagnosis categories was informed by clinical rationale, as well as by the observed mortality rates for CCS categories. For example, the musculoskeletal category is relatively large because it combines several low-risk CCS categories including diagnoses related to back, knee, facial, and extremity injury or illness, but hip fracture is kept as a separate category due to its higher associated mortality.*
Model Performance

In total, across the 4 SMR models, we assessed model performance for 24 different scenarios in the validation data, as defined by the model of interest, time-period of interest, and (for the ICU models only) level of intensive care available (Table 2). Overall, the c-statistic ranged from 0.848 to 0.918 across the 24 scenarios, indicating that model performance was consistently strong. When examining nested models for the SMR-30 model, c-statistic was 0.840 in a basic administrative model, 0.853 in an enhanced administrative model, and 0.870 in the full model—showing the added benefit of including physiological data (Supplemental Table 6).

The calibration plot (Fig. 2) and Table 3 show that the acute care SMR-30 model was well-calibrated in the validation cohort. There were 16,036 deaths (4.29% mortality) in the SMR-30 validation cohort versus 17,458 predicted deaths (4.67%), reflecting 0.38% over-prediction. Across deciles of predicted risk, the absolute difference in observed versus predicted percent mortality was a mean of 0.38%, with a maximum error of 1.81% seen in the highest-risk decile. Calibration plots and tables for the acute care SMR, ICU SMR, and ICU SMR-30 models are presented in Supplemental Figures 1–3 and Supplemental Tables 7–9. Similar to the acute care SMR-30 model, observed versus predicted mortality was within 1.0% for the acute care SMR, ICU SMR, and ICU SMR-30 validation cohorts. Additionally, mean error across risk deciles was <1.0%, and error greater than 1.0% was seen in only the highest risk decile of each model.

DISCUSSION

The VA was among the first healthcare systems to measure and report risk-adjusted ICU mortality. And, over the past 15 years, the VA’s mortality model has been updated, re-calibrated annually, and adapted for risk-adjustment of all VA acute care hospitalizations. In this study, we show that the VA’s mortality models (acute care SMR-30, acute care SMR, ICU SMR-30, and ICU SMR) can strongly discriminate in-hospital and 30-day mortality. Furthermore, the models are well-calibrated, with observed versus predicted mortality within 1% for all but the highest risk decile. Overall, the performance of each of the four VA mortality models is similar to the initial VA ICU mortality model,11,19 similar to other physiology-based mortality models such as APACHE,4,7,20,21 and superior to risk models using administrative data only22,23. Likewise, the relatively lower calibration for the top risk-decile is consistent with other physiologic risk-adjustment models.7

A second major finding of our study is that the rates of inpatient and 30-day mortality for eligible acute care hospitalizations are relatively low (1.8% and 4.3%), which limits the ability to differentiate hospitals statistically based on mortality.24 Nonetheless, mortality monitoring is a critical component of quality measurement given the importance of identifying any hospitals with statistically greater-than-predicted mortality, as well as identifying numeric differences that may trigger further review to identify and remediate any problems before statistically significant differences in mortality arise. The strong performance of the VA mortality models lends credibility to their use in hospital evaluation and their ability to
account for differences in patient case-mix across hospitals. However, mortality does not equate to quality. Greater-than-predicted mortality may occur for a number of reasons, not all of which reflect poor care. Thus, these mortality models serve as a warning tool to trigger deeper review, but are not a standalone marker of hospital quality. The results must be contextualized and evaluated alongside other metrics. Several aspects of the modeling approach warrant further discussion. First, hospitalizations were assigned to one of 51 mutually exclusive admission diagnosis categories based on their admitting diagnosis, similar to the approach taken in the Kaiser Permanente Northern California’s risk-adjustment model. By contrast, other models have used hierarchical approaches to classifying admission diagnoses, which are not based on diagnostic codes and must therefore be incorporated into workflow. For example, the UK’s Intensive Care National Audit and Research Centre’s coding method classifies ICU admissions by type (surgical, medical), system (e.g., respiratory), site (e.g., lungs), process (e.g., infection), and condition (e.g., bacterial pneumonia). While there are 741 unique conditions in this approach, five conditions accounted for 19.4% of all admissions, and the majority of unique conditions were ultimately excluded from the model to due imprecision in estimating the association between the condition and mortality (in which case hospitalizations are classified by the body system). The VA admission diagnosis categories each include one or more clinical classification software (CCS) diagnosis categories. The merging of CCS categories into admission diagnosis categories was informed by clinical rationale, as well as by the observed mortality rates for CCS categories. For this reason, for example, upper and lower extremity fractures were merged together, while hip fracture was kept as a separate diagnosis category due to its higher associated mortality. The mapping of individual admission diagnoses to admission diagnosis categories via the CCS categories facilitates assignment of any new ICD-10-CM codes to an admission diagnosis category since the Agency for Healthcare Research and Quality updates the clinical classification software on an ongoing basis. While some clinicians may prefer more granular admission diagnosis groupings, each group must have a sufficient number of observations to estimate the association with mortality—limiting the number of discrete diagnosis groupings that can be used in practice. Instead, the physiologic variables serve to further differentiate the hospitalizations within the same diagnosis category, and consistently provide far more prognostic information than the diagnosis category.

Second, hospitalizations were excluded from the VA model if the patient had a hospice encounter in the year preceding or on the calendar day of admission. Only 1.5% and 0.1% of otherwise eligible hospitalizations were excluded, respectively, due to hospice encounters prior to or on the day of admission. First, hospitalizations were assigned to one of 51 mutually exclusive admission diagnosis categories based on their admitting diagnosis, similar to the approach taken in the Kaiser Permanente Northern California’s risk-adjustment model. By contrast, other models have used hierarchical approaches to classifying admission diagnoses, which are not based on diagnostic codes and must therefore be incorporated into workflow. For example, the UK’s Intensive Care National Audit and Research Centre’s coding method classifies ICU admissions by type (surgical, medical), system (e.g., respiratory), site (e.g., lungs), process (e.g., infection), and condition (e.g., bacterial pneumonia). While there are 741 unique conditions in this approach, five conditions accounted for 19.4% of all admissions, and the majority of unique conditions were ultimately excluded from the model to due imprecision in estimating the association between the condition and mortality (in which case hospitalizations are classified by the body system). The VA admission diagnosis categories each include one or more clinical classification software (CCS) diagnosis categories. The merging of CCS categories into admission diagnosis categories was informed by clinical rationale, as well as by the observed mortality rates for CCS categories. For this reason, for example, upper and lower extremity fractures were merged together, while hip fracture was kept as a separate diagnosis category due to its higher associated mortality. The mapping of individual admission diagnoses to admission diagnosis categories via the CCS categories facilitates assignment of any new ICD-10-CM codes to an admission diagnosis category since the Agency for Healthcare Research and Quality updates the clinical classification software on an ongoing basis. While some clinicians may prefer more granular admission diagnosis groupings, each group must have a sufficient number of observations to estimate the association with mortality—limiting the number of discrete diagnosis groupings that can be used in practice. Instead, the physiologic variables serve to further differentiate the hospitalizations within the same diagnosis category, and consistently provide far more prognostic information than the diagnosis category.

Table 2 Performance of the SMR Models in Derivation and Validation Cohorts

| Model and Cohort                        | N (|%) | C stat | H-L GOF chi-square | Brier’s score |
|----------------------------------------|-----|--------|-------------------|--------------|
| Acute Care SMR-30 derivation           | 769710 | 33180 (4.31) | 0.871 | 187.7 | 0.035 |
| Acute Care SMR-30 validation, full year | 373791 | 16036 (4.29) | 0.870 | 211.6 | 0.035 |
| Acute Care SMR-30 validation, Q1       | 92338  | 4038 (4.37)  | 0.871 | 39.1  | 0.035 |
| Acute Care SMR-30 validation, Q2       | 94640  | 4258 (4.50)  | 0.869 | 49.1  | 0.037 |
| Acute Care SMR-30 validation, Q3       | 95269  | 4023 (4.22)  | 0.867 | 66.3  | 0.034 |
| Acute Care SMR-30 validation, Q4       | 91544  | 3717 (4.06)  | 0.873 | 88.4  | 0.033 |
| ICU SMR-30 derivation                  | 151426 | 13635 (9.00) | 0.871 | 155.3 | 0.063 |
| ICU SMR-30 validation                   | 72160  | 6638 (9.20)  | 0.864 | 110.6 | 0.066 |
| ICU SMR-30 validation, ICU level 1/2    | 62806  | 5746 (9.15)  | 0.866 | 103.0 | 0.065 |
| ICU SMR-30 validation, ICU level 3/4    | 9354   | 892 (9.54)   | 0.848 | 18.0  | 0.071 |
| ICU SMR-30 validation, Q1              | 17981  | 1652 (9.19)  | 0.864 | 29.3  | 0.066 |
| ICU SMR-30 validation, Q2              | 18704  | 1787 (9.55)  | 0.863 | 32.1  | 0.069 |
| ICU SMR-30 validation, Q3              | 18276  | 1681 (9.20)  | 0.865 | 36.3  | 0.066 |
| ICU SMR-30 validation, Q4              | 17199  | 1518 (8.83)  | 0.862 | 31.8  | 0.064 |
| Acute Care SMR derivation              | 853194 | 15429 (1.81) | 0.916 | 247.6 | 0.015 |
| Acute Care SMR validation, Q1          | 102049 | 1802 (1.77)  | 0.918 | 57.8  | 0.015 |
| Acute Care SMR validation, Q2          | 104446 | 1960 (1.88)  | 0.911 | 35.4  | 0.016 |
| Acute Care SMR validation, Q3          | 105513 | 1759 (1.67)  | 0.912 | 75.0  | 0.014 |
| Acute Care SMR validation, Q4          | 101321 | 1652 (1.65)  | 0.914 | 77.6  | 0.014 |
| ICU SMR derivation                     | 152914 | 9641 (6.30)  | 0.895 | 229.7 | 0.046 |
| ICU SMR validation                     | 72752  | 4555 (6.26)  | 0.887 | 153.0 | 0.047 |
| ICU SMR validation, ICU level 1/2      | 63873  | 4122 (6.45)  | 0.887 | 128.0 | 0.048 |
| ICU SMR validation, ICU level 3/4      | 8879   | 433 (4.88)   | 0.887 | 41.7  | 0.039 |
| ICU SMR validation, Q1                 | 18125  | 1138 (6.28)  | 0.887 | 23.8  | 0.047 |
| ICU SMR validation, Q2                 | 18881  | 1259 (6.67)  | 0.886 | 49.4  | 0.050 |
| ICU SMR validation, Q3                 | 18451  | 1145 (6.21)  | 0.888 | 42.0  | 0.046 |
| ICU SMR validation, Q4                 | 17295  | 1013 (5.86)  | 0.887 | 61.3  | 0.045 |

ICU, intensive care unit; SMR, standardized mortality ratio; Q, quarter; C stat, C statistic; H-L GOF chi-square, Hosmer Lemeshow goodness-of-fit C statistic chi-square value where a lower value is better and the size of the value is linearly related to the size of the cohort; all H-L GOF chi-square values were significantly different (p<0.05). Level 1/2, ICUs who can provide most subspecialty medical and surgical Care; level 3/4: ICUs in smaller hospitals which lack some or many medical and surgical subspecialty care.
admission. Furthermore, in exploratory analyses without this exclusion, the mortality models perform similarly since the model consistently identifies patients referred to hospice as having a high risk for mortality. Some clinicians may argue for expanding the hospice exclusion to also exclude patients with who transition to hospice at later points in hospitalization. However, a majority of patients who die during inpatient hospitalization are transitioned to comfort-only measures or have treatment limitations initiated prior to death, such that broad exclusions of patients with hospice care could substantially limit the ability to differentiate mortality outcomes across hospitals. Initiation of hospice care during or before the calendar day of admission was felt to be the fairest approach. However, the best approach to incorporating treatment limitations into hospital performance assessment remains an area of ongoing study, and best practices are yet to be defined. Through the VA’s Life-Sustaining Treatment Decisions Initiative, there is a national effort to elicit, honor, and document Veteran’s values, goals, and healthcare treatment preferences. The initiative’s harmonized approach to

Table 3 Observed vs Predicted Mortality in the SMR-30 Validation Cohort Using 10 Equally Size Bins Defined by Decile of Predicted Risk

| Risk decile | Predicted risk (lowest, highest) | Hospitalizations, N | Observed deaths, N (% | Predicted deaths, N (% | Difference*, N (%) |
|-------------|----------------------------------|---------------------|------------------------|------------------------|-------------------|
| 1           | (0.000–0.002)                    | 37,379              | 62 (0.17)              | 47 (0.13)              | 15 (0.04)         |
| 2           | (0.002–0.004)                    | 37,379              | 94 (0.25)              | 118 (0.32)             | −24 (−0.06)       |
| 3           | (0.004–0.007)                    | 37,379              | 154 (0.41)             | 211 (0.56)             | −57 (−0.15)       |
| 4           | (0.007–0.011)                    | 37,379              | 252 (0.67)             | 332 (0.89)             | −80 (−0.21)       |
| 5           | (0.011–0.016)                    | 37,379              | 318 (1.03)             | 495 (1.33)             | −111 (−0.30)      |
| 6           | (0.016–0.023)                    | 37,380              | 541 (1.45)             | 725 (1.94)             | −184 (−0.49)      |
| 7           | (0.023–0.035)                    | 37,379              | 926 (2.48)             | 1077 (2.88)            | −151 (−0.40)      |
| 8           | (0.035–0.057)                    | 37,379              | 1572 (4.21)            | 1686 (4.51)            | −114 (−0.30)      |
| 9           | (0.057–0.114)                    | 37,379              | 2951 (7.89)            | 2991 (8.00)            | −40 (−0.11)       |
| 10          | (0.114–0.987)                    | 37,379              | 9100 (24.35)           | 9775 (26.15)           | −675 (−1.81)      |
| 1–10        | (0.000–0.987)                    | 373,791             | 16036 (4.29)           | 17458 (4.67)           | −1422 (−0.38)     |

* Differences reflect the observed minus predicted mortality. Negative values indicate that the model over-predicted mortality, while positive values indicate that the model under-predicted mortality.

The expected (mean) absolute calibration error across risk decile was 0.38%, while the maximum calibration error (observed in the highest risk decile) was 1.81%.
documenting treatment preferences across VA hospitals may allow for future incorporation of treatment preferences documented at hospital admission to be incorporated into performance measurement.

Third, physiological variables are currently incorporated into the VA’s mortality models as categorical variables, which allow for ready interpretation of the association between physiologic derangements and the risk of mortality. By contrast, some other models (and VA’s initial ICU mortality model) use cubic splines— which allow for more flexible parameterization of the physiologic variables, but come at the cost of decreased transparency, since the model output is not readily interpretable. The opaqueness of regression models has been cited as a key drawback of regression-based performance assessment, which may reduce credibility and motivation to act on the assessment results. Thus, given the trade-offs between statistical precision and interpretability, there is no “best approach” to the incorporation of physiologic variables. The current VA mortality models using categorical physiologic variables perform similarly to the prior VA ICU mortality model using cubic splines, indicating that the loss of performance is minimal, and therefore, the added statistical precision may not be worth the added complexity of interpretation.

There are some limitations to acknowledge. First, there are many drawbacks to the use of risk-adjusted mortality for measuring hospital quality, which are discussed in detail elsewhere, including low power, inability to differentiate preventable versus unpreventable deaths, and the imperfect correlation between process and outcome measures. Despite these limitations, monitoring risk-adjusted mortality is an important component of quality improvement, as discussed above. Secondly, the VA’s acute care mortality models incorporate 8 physiologic variables (sodium, BUN, creatinine, glucose, albumin, bilirubin, white blood cell count, and hematocrit), with an additional three values (PaO₂, PaCO₂, and pH) included in the ICU models. These physiologic variables are commonly included in other physiologic risk-adjustment models and have high clinical face value, but are not fully comprehensive. Additional physiologic measurements such as vital signs (heart rate, blood pressure, respiratory rate, pulse oximetry), mental status, and blood lactate measurement may provide additional prognostic information. Vital signs and mental status cannot be readily incorporated into the VA’s mortality model at present because they are recorded outside the electronic health record (e.g., in ICU-specific programs) in many units, leading to systematic missingness that could bias risk adjustment. Lactate measurements, however, are available in the electronic health record, and are currently being considered for incorporation into VA mortality models. Finally, the VA patient population has unique demographics, risk factors, and comorbidity profile, so this model may not generalize to other settings. Indeed, model performance often degrades when applying models to new settings, underscoring the need for periodic model evaluation and recalibration and the benefit of developing context-specific models rather than simply applying “off-the-shelf” risk tools.

CONCLUSIONS

We have shown that the VA’s mortality models, which incorporate patient physiology and are recalibrated annually using hospitalizations from the prior 2 years, are highly predictive and have good calibration both overall and across risk deciles. The strong model performance underscores the benefit of physiologic data and the development of models in the population and setting in which they will be used.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s11606-021-07377-1.

Acknowledgements: The authors would like to thank Joseph Francis, MD, MPH; Marthe Moseley, PhD, RN, CCRN-K, CCNS, and Karen Sovern, RN, MSN.

Conflict of Interest: The authors declare that they do not have a conflict of interest.

Disclaimer: This manuscript represents the views of the authors and does not necessarily reflect the position of the Department of Veterans Affairs or the US government.

REFERENCES

1. Fihn SD, Francis J, Clancy C, et al. Insights from advanced analytics at the Veterans Health Administration. Health Aff (Millwood). 2014;33(12):203-211.
2. Render ML, Kim HM, Welsh DE, et al. Automated intensive care unit risk adjustment: results from a National Veterans Affairs study. Crit Care Med. 2003;31(6):1638-1646.
3. Render ML, Deddens J, Freyberg R, et al. Veterans Affairs intensive care unit risk adjustment model: validation, updating, recalibration. Crit Care Med. 2008;36(4):1031-1042.
4. Zimmerman JE, Kramer AA, McNair DS, Malila FM. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today’s critically ill patients. Crit Care Med. 2006;34:1297-1310.
5. Harrison DA, Brady AR, Parry GJ, Carpenter JR, Rowan K. Recalibration of risk prediction models in a large multicenter cohort of admissions to adult, general critical care units in the United Kingdom. Crit Care Med. 2006;34(5):1378-1388.
6. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128-138.
7. Escobar GJ, Greene JD, Scheirer P, Gardner MN, Draper D, Kipnis P. Risk-adjusting hospital inpatient mortality using automated inpatient, outpatient, and laboratory databases. Med Care. 2008;46(3):232-239.
8. HCUP. Beta Clinical Classifications Software (CCS) for ICD-10-CM/PCS. https://www.hcup-us.ahrq.gov/toolssoftware/ccs10/ccs10.jsp. Accessed September 11, 2019.

9. Eliahu A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27.

10. Healthcare Cost and Utilization Project. Eliahu Comorbidity Software Redefined for ICD-10-CM. Available at https://www.hcup-us.ahrq.gov/toolssoftware/comorbidityicd10/comorbidity_icd10.jsp [accessed May 2, 2021]. Accessed.

11. Render ML, Kim HM, Welsh DE, et al. Automated intensive care unit risk adjustment: results from a National Veterans Affairs study. Critical Care Medicine. 2003;31(6):1638-1646.

12. Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. BMJ. 2009;338:b605.

13. Royston P, Moons KG, Altman DG, Vergouwe Y. Prognosis and prognostic research: Developing a prognostic model. BMJ. 2009;338:b604.

14. Huang Y, Li W, Macheret F, Gabriel RA, Ohno-Machado L. A tutorial on calibration measurements and calibration models for clinical prediction models. J Am Med Inform Assoc. 2020;27(4):621-633.

15. Hosmer DW, Lemeshow S. Applied logistic regression. Wiley series in probability and mathematical statistics Applied probability and statistics. 1989.

16. Hosmer DW, Lemeshow S. Applied logistic regression. Wiley series in probability and statistics Texts and references section. 2000.

17. Hilbert G, Gruson D, Vargas F, et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med. 2001;344:481-487.

18. Almenoff P, Sales A, Rounds S, et al. Intensive care services in the Veterans Health Administration. Chest. 2007;132:1455-1462.

19. Elder NC, Brungs SM, Nagy M, Kudel I, Render ML. Intensive care unit nurses’ perceptions of safety after a highly specific safety intervention. Qual Saf Health Care. 2008;17:25-30.

20. Liu V, Turk BJ, Ragins AL, Kipnis P, Escobar GJ. An electronic Simplified Acute Physiology Score-based risk adjustment score for critical illness in an integrated healthcare system. Critical Care Medicine. 2013;41:41-48.

21. Harrison DA, Parry GJ, Carpenter JR, Short A, Rowan K. A new risk prediction model for critical care: the Intensive Care National Audit & Research Centre (ICNARC) model. Crit Care Med. 2007;35(4):1091-1098.

22. Yale New Haven Health System Center for Outcomes Research & Evaluation (NYHSS/CORE), Hospital-Wide (All-Condition, All-Procedure) Risk-Standardized Mortality Measure: Draft Measure Methodology for Interim Public Comment. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/Downloads/Hospital-Wide-All-Condition_All-Procedure_Risk-Standardized-Mortality-Measure_Public-Comment.pdf. Published 2016. Accessed November 24, 2021.

23. Krumholz HM, Coppi AC, Warner F, et al. Comparative Effectiveness of New Approaches to Improve Mortality Risk Models From Medicare Claims Data. JAMA Netw Open. 2019;2(7):e197314.

24. Krell RW, Hozain A, Kao LS, Dimick JB. Reliability of risk-adjusted outcomes for profiling hospital surgical quality. JAMA Surg. 2014;149(5):467-474.

25. Young JD, Goldfrad C, Rowan K. Development and testing of a hierarchical method to code the reason for admission to intensive care units: the ICNARC Coding Method. Intensive Care National Audit & Research Centre. Br J Anaesth. 2001;87(4):543-548.

26. Walkey AJ, Weinberg J, Wiener RS, Cooke CR, Lindenuer PK. Association of Do-Not-Resuscitate Orders and Hospital Mortality Rate Among Patients With Pneumonia. JAMA Intern Med. 2016;176:97-104.

27. Pronovost PJ, Austin JM, Cassel CK, et al. Fostering Transparency in Outcomes, Quality, Safety, and Costs: A Vital Direction for Health and Health Care | National Academy of Medicine. 2016.

28. Lilford R, Pronovost P. Using hospital mortality rates to judge hospital performance: a bad idea that just won’t go away. BMJ. 2010;340:c2016.

29. Holloway RG, Quill TE. Mortality as a measure of quality: implications for palliative and end-of-life care. JAMA. 2007;298(7):802-804.

30. Escobar GJ, Gardner MN, Greene JD, Draper D, Kipnis P. Risk-adjusting hospital mortality using a comprehensive electronic record in an integrated health care delivery system. Medical Care. 2013;51:446-453.

Publisher’s Note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.